After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 wasn’t slow—it was actually quite normal. “This is a really rational IPO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback